Tvardi Therapeutics (TVRD) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing novel, oral small molecule therapies targeting STAT3 for fibrosis-driven diseases with significant unmet need.

• Lead candidate TTI-101 in Phase 2 trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC); TTI-109, a related STAT3 inhibitor, in preclinical/IND stage.

• Focus on direct STAT3 inhibition, a historically undruggable target, with differentiated mechanism and oral dosing.

• Pipeline includes additional indications in fibrosis and oncology, with plans for further expansion.

Financial performance and metrics

• No revenue generated to date; company has incurred significant net losses since inception.

• Net loss of $29.4M for 2024 and $5.4M for the six months ended June 30, 2025; accumulated deficit of $97.6M as of June 30, 2025.

• Cash and cash equivalents of $20.6M and short-term investments of $20.3M as of June 30, 2025.

• Net income of $4.2M for Q2 2025 due to fair value changes in Convertible Notes; expects continued operating losses for the foreseeable future.

Use of proceeds and capital allocation

• IPO is a resale registration for 2,084,117 shares by selling stockholders; company will not receive proceeds from these sales.

• Proceeds from prior financings and merger used to fund R&D, clinical trials, and general operations.

• Additional capital required to fund ongoing and planned clinical trials and operations; plans to seek further funding through equity, debt, or strategic partnerships.